Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Russian Academy of Medical Sciences and Lomonosov Moscow State University in the 1980s. It is structurally a fragment of adrenocorticotropic hormone (ACTH residues 4-7) with a Pro-Gly-Pro C-terminal extension that makes it metabolically stable — without the hormonal effects of full ACTH.

Is Semax an approved medicine?

In the Russian Federation, Semax is on the Russian register of essential medicines and is used clinically for stroke (intranasal 0.1% solution) and cognitive disorders. Outside Russia and CIS countries, Semax is not approved as a medicine and is sold strictly as a research peptide.

What does the published research show?

The strongest mechanistic data documents upregulation of BDNF and NGF in rat brain (Dolotov et al., Shadrina et al.), neuroprotection in stroke and hypoxia models, and modulation of dopaminergic and serotonergic systems. Behavioural studies in rats show effects on learning, attention, and stress response.

Why is the Semax literature so heavily Russian?

Semax was developed in Russia and the bulk of clinical research has been published in Russian journals — many not translated to English. Western-indexed papers exist but are a fraction of the total literature. This means a researcher relying only on PubMed will see less than the full picture. It also means Western RCTs to Western methodological standards are thinner.

How is Semax typically administered in research?

Intranasal administration is the most-documented route — Semax has acceptable bioavailability via nasal mucosa and the route is used clinically in Russia. Reconstituted solution is delivered as drops into the nostril. Parenteral routes are less common in the published research.

Home › Blog › Semax Research Guide

CNS Research

Semax: The Russian ACTH-Derived Nootropic Peptide

6 June 20269 min readREVIVE LAB UAE Research Desk

Semax sits in an unusual position in the research peptide market. In Russia it's an approved medicine on the essential drugs register, used clinically for stroke and cognitive disorders for over 30 years. Everywhere else, it's a research peptide with a literature heavily concentrated in Russian-language journals. This is what the published English-indexed research actually documents.

For research use only outside the Russian Federation and CIS countries. All references below are peer-reviewed animal-model studies or Russian-published clinical work. Not intended for human or veterinary use as a medicine outside its approved jurisdictions.

1. Structure and origin

Semax is a synthetic heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The first four residues (Met-Glu-His-Phe) correspond to residues 4–7 of natural adrenocorticotropic hormone (ACTH). The C-terminal Pro-Gly-Pro extension was added by the developers at the Institute of Molecular Genetics, Russian Academy of Sciences, and Lomonosov Moscow State University to make the molecule metabolically stable — natural ACTH fragments are rapidly degraded.

The structural key: by stripping ACTH down to residues 4–7, Semax loses the hormonal effects of full ACTH (no adrenal stimulation, no glucocorticoid release) but retains the central nervous system effects that were initially attributed to the ACTH(4–10) fragment.

2. The mechanism — BDNF, NGF, and dopaminergic modulation

Neurotrophin upregulation

The most-cited mechanistic finding is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in rat brain. Dolotov OV et al. published a series of papers documenting BDNF mRNA increases in the hippocampus and frontal cortex after Semax administration in rats. Shadrina MI et al. extended this with gene-expression array work showing that Semax modulates expression of dozens of CNS-related genes including BDNF, NGF, and synaptic proteins.

Dopaminergic and serotonergic effects

Eremin KO, Bobyntsev II, and colleagues documented Semax effects on dopaminergic transmission in rat models — modulation of extracellular dopamine in the nucleus accumbens, effects on D1 and D2 receptor signalling. Behavioural correlates include changes in attention, learning, and stress-response measures in standard rodent paradigms (Morris water maze, passive avoidance, open field).

Neuroprotection in stroke models

Semax's clinical use in Russia is grounded in animal-model stroke work showing reduced infarct volume and improved neurological recovery in middle cerebral artery occlusion (MCAO) models. The mechanism converges on the BDNF/NGF pathway and anti-inflammatory effects on microglia.

3. The Russian clinical literature

Semax has been used clinically in the Russian Federation for over 30 years. Russian peer-reviewed clinical papers report on its use in:

Ischaemic stroke — administered intranasally during the acute phase. This is the on-label indication.
Cognitive disorders — vascular cognitive impairment, post-stroke cognitive recovery.
Optic nerve atrophy — an unusual but documented Russian clinical use.
Pediatric attention/learning disorders — documented in Russian pediatric neurology literature.

The literature-availability problem: Most Semax clinical and mechanistic research is published in Russian journals — many of which are not indexed in PubMed and not translated. A PubMed search returns a fraction of the total Semax literature. Researchers relying only on English-indexed databases will see less than the full picture, and Western-style RCTs to ICH-GCP standards are thinner than the Russian clinical use volume might suggest.

4. Bioavailability and route

Intranasal administration is the documented and clinical route. Semax has acceptable bioavailability through nasal mucosa, and crosses into the CSF rapidly via the olfactory pathway (avoiding first-pass metabolism). Russian clinical formulations are 0.1% solutions delivered as drops into the nostrils.

Parenteral routes — subcutaneous, intraperitoneal — are used in animal research but are less common than intranasal for clinical work. Oral bioavailability is negligible.

5. What Semax is and isn't compared to other nootropic peptides

Compared to Selank (another Russian-origin peptide, anxiolytic-leaning): structurally distinct — Selank is a Tuftsin analogue. Both share the Pro-Gly-Pro stabilising motif.
Compared to Cerebrolysin: completely different category — Cerebrolysin is a complex porcine brain-derived preparation; Semax is a defined synthetic heptapeptide.
Compared to racetams (piracetam, aniracetam): different mechanism entirely. Racetams are small-molecule AMPA modulators; Semax acts via BDNF/NGF upregulation and ACTH-derived signalling.

6. Practical research considerations

Reconstitution: Bacteriostatic water, standard handling. See reconstitution guide.
Storage: Refrigerated at 2–8 °C after reconstitution. Stable for ~28 days.
Common research route: Intranasal in animal studies replicating the clinical route.
Vial sizes: Typically 10 mg or 30 mg lyophilised.

7. The honest summary

Heptapeptide ACTH(4–7) analogue + Pro-Gly-Pro stabilisation tail.
Russian-approved medicine for stroke and cognitive disorders since the 1990s.
Outside Russia: research peptide, not an approved drug.
Strongest mechanistic data: BDNF/NGF upregulation, dopaminergic modulation, neuroprotection in stroke models.
Literature heavily concentrated in Russian-language journals — English-indexed papers are a partial view.
Western RCTs to ICH-GCP standards are thinner than Russian clinical use volume implies.

References (English-indexed)

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82–86. PubMed
Shadrina MI, Dolotov OV, Grivennikov IA, et al. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115–118. PubMed
Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493–1500. PubMed
Asmarin IP, Nezavibatko VN, Myasoedov NF, et al. Nootropic analog of adrenocorticotropin 4-10-Semax (15 years of experience in development and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420–430. PubMed
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of Semax in acute period of hemispheric ischemic stroke (clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26–34. PubMed

Semax 10 mg — ProductHPLC-verified, COA-backed, 24h UAE delivery Peptide Reconstitution GuideBacteriostatic water, calculation, storage MOTS-c Mitochondrial PeptideAMPK activation and exercise biology BPC-157 Research GuideMechanism and animal evidence